LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

Search

Treace Medical Concepts Inc

Atvērts

1.87

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.81

Max

1.9

Galvenie mērījumi

By Trading Economics

Ienākumi

1.1M

-16M

Pārdošana

2.8M

50M

Peļņas marža

-32.437

Darbinieki

477

EBITDA

1.3M

-12M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+132.8% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 27. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-298M

119M

Iepriekšējā atvēršanas cena

1.87

Iepriekšējā slēgšanas cena

1.87

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Treace Medical Concepts Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. febr. 22:31 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026. g. 18. febr. 22:18 UTC

Peļņas

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026. g. 18. febr. 22:11 UTC

Peļņas

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026. g. 18. febr. 21:52 UTC

Peļņas

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026. g. 18. febr. 23:56 UTC

Tirgus saruna

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026. g. 18. febr. 23:34 UTC

Tirgus saruna
Peļņas

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026. g. 18. febr. 23:33 UTC

Tirgus saruna

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026. g. 18. febr. 23:32 UTC

Tirgus saruna

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026. g. 18. febr. 22:45 UTC

Peļņas

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026. g. 18. febr. 22:44 UTC

Tirgus saruna

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q EPS $1.18 >NTR.T

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q Sales $5.34B >NTR.T

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q EPS $1.07 >PAAS

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q Rev $1.18B >PAAS

2026. g. 18. febr. 22:30 UTC

Peļņas

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026. g. 18. febr. 22:29 UTC

Peļņas

Kinross Gold 4Q EPS 75c >K.T

2026. g. 18. febr. 22:22 UTC

Peļņas

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026. g. 18. febr. 22:22 UTC

Tirgus saruna

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026. g. 18. febr. 22:16 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026. g. 18. febr. 22:05 UTC

Peļņas

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026. g. 18. febr. 22:03 UTC

Peļņas

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Sales $929M >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Adj EPS 67c >KGC

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Sales $2.02B >KGC

2026. g. 18. febr. 21:56 UTC

Peļņas

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026. g. 18. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Treace Medical Concepts Inc Prognoze

Cenas mērķis

By TipRanks

132.8% augšup

Prognoze 12 mēnešiem

Vidējais 4.33 USD  132.8%

Augstākais 7.5 USD

Zemākais 2.5 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Treace Medical Concepts Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

1

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

7.16 / 7.65Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Treace Medical Concepts Inc

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
help-icon Live chat